ATE432280T1 - Imidazopyridinderivate als melanocortinrezeptoragonisten - Google Patents

Imidazopyridinderivate als melanocortinrezeptoragonisten

Info

Publication number
ATE432280T1
ATE432280T1 AT04742386T AT04742386T ATE432280T1 AT E432280 T1 ATE432280 T1 AT E432280T1 AT 04742386 T AT04742386 T AT 04742386T AT 04742386 T AT04742386 T AT 04742386T AT E432280 T1 ATE432280 T1 AT E432280T1
Authority
AT
Austria
Prior art keywords
receptor agonists
melanocortin receptor
imidazopyridine derivatives
imidazopyridine
derivatives
Prior art date
Application number
AT04742386T
Other languages
German (de)
English (en)
Inventor
Lydie Poitout
Valerie Brault
Carole Sackur
Pierre Roubert
Pascale Plas
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE432280T1 publication Critical patent/ATE432280T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
AT04742386T 2003-03-31 2004-03-29 Imidazopyridinderivate als melanocortinrezeptoragonisten ATE432280T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0303924A FR2852957B1 (fr) 2003-03-31 2003-03-31 Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
PCT/FR2004/000785 WO2004089951A1 (fr) 2003-03-31 2004-03-29 Derives d’imidazo-pyridine ayant une affinite sur des recepteurs de la melanocortine

Publications (1)

Publication Number Publication Date
ATE432280T1 true ATE432280T1 (de) 2009-06-15

Family

ID=32947292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04742386T ATE432280T1 (de) 2003-03-31 2004-03-29 Imidazopyridinderivate als melanocortinrezeptoragonisten

Country Status (17)

Country Link
US (1) US7495009B2 (enExample)
EP (1) EP1615925B1 (enExample)
JP (1) JP4711948B2 (enExample)
KR (1) KR101102742B1 (enExample)
CN (1) CN100455581C (enExample)
AT (1) ATE432280T1 (enExample)
AU (1) AU2004228416B9 (enExample)
BR (1) BRPI0408817A (enExample)
CA (1) CA2520855C (enExample)
DE (1) DE602004021247D1 (enExample)
ES (1) ES2327929T3 (enExample)
FR (1) FR2852957B1 (enExample)
IL (1) IL170834A (enExample)
MX (1) MXPA05010278A (enExample)
NZ (1) NZ542763A (enExample)
RU (1) RU2358974C2 (enExample)
WO (1) WO2004089951A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
EP2168965A1 (en) * 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
RU2013109143A (ru) 2010-08-05 2014-09-10 Амджен Инк. Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
HK1206735A1 (en) * 2012-04-06 2016-01-15 辉瑞公司 Diacylglycerol acyltransferase 2 inhibitors
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US10196425B2 (en) 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
SG11201704872RA (en) 2014-12-18 2017-07-28 Genzyme Corp Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
KR20200121823A (ko) * 2018-02-16 2020-10-26 유씨비 바이오파마 에스알엘 약학적 6,5 헤테로비시클릭 고리 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4416433A1 (de) * 1994-05-10 1995-11-16 Hoechst Ag Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
AU766191B2 (en) * 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
JP2003528810A (ja) * 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク メラノコルチン−４受容体結合化合物及びその使用方法
AU2001236919A1 (en) 2000-02-09 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses
JP2003534377A (ja) * 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
IL156031A0 (en) * 2000-12-15 2003-12-23 Vertex Pharma Fused heterocyclic derivatives and pharmaceutical compositions containing the same
EP1465888A2 (en) * 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues

Also Published As

Publication number Publication date
NZ542763A (en) 2007-11-30
RU2358974C2 (ru) 2009-06-20
CA2520855A1 (fr) 2004-10-21
EP1615925B1 (fr) 2009-05-27
US20060173036A1 (en) 2006-08-03
CN1768058A (zh) 2006-05-03
AU2004228416B2 (en) 2010-02-11
CN100455581C (zh) 2009-01-28
JP4711948B2 (ja) 2011-06-29
AU2004228416B8 (en) 2010-03-04
CA2520855C (fr) 2014-05-13
US7495009B2 (en) 2009-02-24
HK1090640A1 (zh) 2006-12-29
KR101102742B1 (ko) 2012-01-05
FR2852957B1 (fr) 2005-06-10
JP2006522076A (ja) 2006-09-28
AU2004228416B9 (en) 2010-03-11
AU2004228416A1 (en) 2004-10-21
WO2004089951A1 (fr) 2004-10-21
MXPA05010278A (es) 2005-11-17
IL170834A (en) 2010-12-30
BRPI0408817A (pt) 2006-04-04
ES2327929T3 (es) 2009-11-05
DE602004021247D1 (de) 2009-07-09
RU2005133441A (ru) 2006-05-10
WO2004089951A8 (fr) 2006-01-12
KR20060002893A (ko) 2006-01-09
EP1615925A1 (fr) 2006-01-18
FR2852957A1 (fr) 2004-10-01

Similar Documents

Publication Publication Date Title
ATE432280T1 (de) Imidazopyridinderivate als melanocortinrezeptoragonisten
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
DK2064348T3 (da) Profilering af receptorfamilie
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
NO20083153L (no) Kjemiske forbindelser
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
ATE384697T1 (de) 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
ES2335410T8 (es) Derivados de aminopropanol.
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
TW200800967A (en) Benzimidazole thiophene compounds
EP1809284A4 (en) Niacin receptor agonists, compositions containing such compounds and treatment methods
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
TW200740814A (en) Compounds
NO20073369L (no) Modulatorer av muskarinreseptorer
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
MEP34308A (en) Oral formulations of cladribine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties